Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins by Rockstroh, Alexandra et al.
 
 
 University of Groningen
Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins
Rockstroh, Alexandra; Barzon, Luisa; Kumbukgolla, Widuranga; Su, Hoang Xuan; Lizarazo,
Erley; Vincenti-Gonzalez, Maria Fernanda; Tami, Adriana; Ornelas, Alice M. M.; Aguiar,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Rockstroh, A., Barzon, L., Kumbukgolla, W., Su, H. X., Lizarazo, E., Vincenti-Gonzalez, M. F., Tami, A.,
Ornelas, A. M. M., Aguiar, R. S., Cadar, D., Schmidt-Chanasit, J., & Ulbert, S. (2019). Dengue Virus IgM
Serotyping by ELISA with Recombinant Mutant Envelope Proteins. Emerging Infectious Diseases, 25(1),
112-115. https://doi.org/10.3201/eid2501.180605
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
112 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 1, January 2019
DISPATCHES
Alexandra Rockstroh, Luisa Barzon,  
Widuranga Kumbukgolla, Hoang Xuan Su,  
Erley Lizarazo, Maria Fernanda  
Vincenti-Gonzalez, Adriana Tami,  
Alice M.M. Ornelas, Renato Santana Aguiar, 
Daniel Cadar, Jonas Schmidt-Chanasit,  
Sebastian Ulbert
We developed an IgM-based ELISA that identifies the den-
gue virus serotype of recent infections. Dominant serotypes 
were detectable in 91.1% of samples from travelers and 
86.5% of samples from residents of endemic regions; 97.1% 
corresponded to the serotype identified by PCR. This ELISA 
enables more accurate reporting of epidemiologic findings.
Dengue virus (DENV) is an arthropodborne flavivirus that is endemic in tropical and subtropical regions, 
causing hundreds of millions of infections annually (1). 
It is subdivided into 4 serotypes, DENV-1–4. After infec-
tion, patients have lifelong immunity against the homolo-
gous serotype but remain susceptible to infections with 
the others (2). Such secondary infections have been shown 
to be a risk factor for severe dengue with life-threatening 
clinical manifestations, including dengue hemorrhagic 
fever or dengue shock syndrome (3). Thus, monitoring 
the serotype is essential for outbreak management, epi-
demiologic studies, and patient care. Analyses are often 
performed by using direct virus detection methods, such 
as PCR and nonstructural protein 1 (NS1) antigen capture 
(4). Despite the high specificities of these assays, their 
main disadvantages include a rather small diagnostic win-
dow for detection and, for NS1 antigen capture tests, low 
sensitivities during secondary DENV infections (5). Iden-
tification of the infecting serotype by serologic methods 
is hampered by the cross-reactivity of antibodies elicited 
by the immune response against flaviviruses (6). Previ-
ous reports have shown that the insertion of mutations in 
the conserved fusion loop domain of flavivirus envelope 
proteins reduces this cross-reactivity in diagnostic testing 
(7–9). Using this method, we developed a DENV-specific 
ELISA capable of differentiating DENV from other clini-
cally relevant flaviviruses, such as Zika virus, West Nile 
virus, and tick-borne encephalitis virus (10). In this study, 
we evaluated the potential of this technique to distinguish 
the 4 DENV serotypes during the acute phase of infection 
on the basis of IgM detection.
The Study
We acquired DENV PCR–confirmed and, thereby, sero-
type-classified serum samples that we divided into 2 groups: 
those from returning travelers with residence in Italy or 
Germany (n = 45), collected from patients 5–60 days after 
symptom onset during 2013–2016; and those from persons 
residing in the DENV-endemic countries of Sri Lanka (n = 
43), Vietnam (n = 24), Venezuela (n = 5), and Brazil (n = 
2), collected from patients 2–8 days after symptom onset 
during 2013–2018. We also had a set of 14 DENV PCR–
negative but NS1-positive (PLATEILA DENGUE NS1 
AG; Bio-Rad, Hercules, CA, USA) serum samples from 
patients in Vietnam that were collected during the same 
outbreak as the other patients from Vietnam with DENV 
PCR–positive test results. Ethics approvals were obtained 
from the respective local authorities for all samples.
We first tested all serum samples with a DENV-specific 
ELISA that used 4 recombinant DENV envelope proteins 
(1 per serotype) containing 4 point mutations in and near 
the conserved fusion loop (called Equad proteins) (9). All 
samples were positive for DENV IgM (S. Ulbert, unpub. 
data). This Equad-based ELISA was previously shown to 
be capable of discriminating DENV from other flaviviruses 
(9,10). We took the Equad antigens from this ELISA 
and created a DENV serotyping ELISA. In brief, we ti-
trated serum samples (1:100–1:12,800 in serial 2-fold 
dilutions) in duplicate on plates coated with DENV-1–4 
Equad proteins (Appendix, https://wwwnc.cdc.gov/EID/
article/25/1/18-0605-App1.pdf) (10). We defined the end-
point titer for every serotype as the last dilution presenting 
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a signal above the cutoff (Appendix Table), which was cal-
culated as the mean plus 2 times the SD of 15 flavivirus-
negative control serum samples (diluted 1:100) acquired 
from Padova University Hospital, Padova, Italy.
Results showed 1 dominant serotype (Figure 1) 
for 91.1% of serum samples from returning travelers 
and 86.5% of serum samples from residents of DENV-
endemic countries (Appendix Figures 1, 2). Compared 
Figure 1. DENV IgM ELISA 
titers, by serotype, for DENV 
PCR–positive serum samples 
from travelers returning to 
Germany or Italy, 2013–2016. 
A) DENV-1; B) DENV-2; C) 
DENV-3; D) DENV-4. Data 
lines indicate average titers; 
error bars indicate SDs. 
The antigens in this ELISA 
were Equad proteins (i.e., 
envelope protein from each 
DENV serotype with 4 amino 
acid changes T76R, Q77E, 
W101R, and L107R). In 
these examples, the highest 
endpoint titers corresponded 
to the DENV serotype 
identified by PCR analysis. 
DENV, dengue virus.
 
Table 1. Dominant serotype determined by DENV serotype–specific IgM ELISA and ELISA specificity, by cohort and serotype,  
2013–2018* 
Cohort, DENV serotype† No. samples 
Dominant serotype, 
no. (%) samples 
Serotype specificity‡ 
No. samples % Samples (95% CI) 
Returning travelers 
 DENV-1 16 14 (87.50) 14 87.50 (61.65–98.45) 
 DENV-2 11 10 (90.91) 8 72.73 (39.03–93.98) 
 DENV-3 10 9 (90) 9 90.00 (55.50–99.75) 
 DENV-4 8 8 (100.00) 7 87.50 (47.35–99.68) 
 All serotypes 45 41 (91.11) 38 84.44 (70.54–93.51) 
Residents in DENV-endemic countries 
 Sri Lanka 
  DENV-1 23 16 (69.57) 16 69.57 (47.08–86.79) 
  DENV-2 14 13 (92.86) 13 92.86 (66.13–99.82) 
  DENV-4 6 6 (100.00) 6 100.00 (54.07–100.00) 
  All serotypes 43 35 (81.40) 35 81.40 (66.60–91.61) 
 Vietnam 
  DENV-1 20 19 (95.00) 19 95.00 (75.13–99.87) 
  DENV-2 4 4 (100.00) 4 100.00 (39.76–100.00) 
  All serotypes 24 23 (95.83) 23 95.83 (78.88–99.89) 
 Venezuela 
  DENV-4 5 4 (80.00) 4 80.00 (23.36–99.49) 
 Brazil 
  DENV-4 2 2 (100.00) 2 100.00 (15.81–100.00) 
 Total 
  DENV-1 43 35 (81.40) 35 81.40 (66.60–91.61) 
  DENV-2 18 17 (94.44) 17 94.44 (72.71–99.86) 
  DENV-4 13 12 (92.31) 12 92.31 (76.55–99.81) 
  All serotypes 74 64 (86.49) 64 86.49 (76.55–93.32) 
Total, all serotypes 119 105 (88.24) 102 85.71 (77.12–91.45) 
*DENV, dengue virus. 
†Determined by PCR. 
‡Determined by correspondence with PCR results. 
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with samples from Vietnam, 15% fewer samples from 
Sri Lanka had a dominant serotype (Table 1). Serum 
samples from patients in Sri Lanka cross-reacted only 
between serotypes 1 and 2 (Appendix Figure 2); how-
ever, these samples were collected at a time when the 
dominant serotype in circulation was switching from 
DENV-1 to DENV-2 after a DENV-1 outbreak in early 
2016 (W. Kumbukgolla, unpub. data). Therefore, this 
result could be explained by preexisting IgM or, alter-
natively, by co-infections. However, co-infections were 
not evident by PCR.
Overall, for 97.1% (102/105) of samples with a 
dominant serotype, ELISA results corresponded with 
PCR results; for patients residing in endemic regions, 
100% (64/64) of the sample results corresponded, and 
for returning travelers, 92.7% (38/41) of the sample re-
sults corresponded (Table 1). When including the sam-
ples for which no dominant serotype was detectable, the 
overall serotype specificity of the Equad-based ELISA 
was 85.7% (Table 1); specificity of the ELISA for serum 
samples from persons in endemic countries was 86.5% 
and for returning travelers 84.4%. Because of the lower 
number of dominant serotypes detected, the cohort from 
Sri Lanka displayed a lower ELISA specificity (81.4%) 
than did the cohort from Vietnam (95.8%). The serotype 
results for the PCR-negative group from Vietnam were 
consistent with the PCR-positive group from Vietnam: 
≈80% DENV-1 and ≈20% DENV-2 (Tables 1, 2).
Analysis of paired serum samples suggests that the re-
sults of this Equad-based ELISA are consistent over time 
and with different initial antibody concentrations (Figure 
2). The IgM serotype initially identified as the dominant 
serotype remained the dominant serotype for at least 8 days 
(and potentially longer) after symptom onset for both re-
turning travelers and patients residing in DENV-endemic 
countries, many of whom probably had secondary DENV 
infections (Appendix Figure 3).
Conclusions
Early identification of the infecting DENV serotype can be 
a critical component of dengue diagnosis that is also es-
sential to pathologic and epidemiologic monitoring of out-
breaks. Because of its long persistence in serum, IgM is a 
preferred diagnostic marker, especially when viral nucleic 
acids and NS1 are no longer detectable. However, serologic 
 
Table 2. Dominant serotype determined by DENV serotype–
specific IgM ELISA among DENV PCR–negative cohort (n = 14), 
Vietnam, 2013–2018* 






13 (92.86) 1 10/14 (71.43) 
2 3/14 (21.43) 
*DENV, dengue virus. 
 
Figure 2. DENV IgM ELISA endpoint titers, by serotype, of paired patient serum samples acquired at 2–4 time points after symptom 
onset, 2013–2018. A–C) Serum samples from returning travelers with residence in Germany: DENV-1 positive (A, B); DENV-2 positive 
(C). D–F) Serum samples from residents of DENV-endemic country Sri Lanka: DENV-2 positive (D, E); DENV-4 positive (F). Data lines 
indicate average titers; error bars indicate SDs. The antigens in the ELISA were Equad proteins (i.e., envelope protein from each DENV 
serotype with 4 amino acid changes T76R, Q77E, W101R, and L107R). DENV, dengue virus.
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determination of the infecting serotype is challenging. 
Detection of neutralizing antibodies remains the standard 
method for DENV identification, but interpretation is com-
plicated by the antigenic sin phenomenon in secondary in-
fections (11). The possibility of using IgM to determine the 
infecting serotype was attempted previously (12–14), but 
results were complicated by low specificities, especially for 
secondary DENV infections. In this study, we analyzed the 
serotype-specific IgM responses to DENV infections in re-
turning travelers and residents in DENV-endemic regions 
using recombinant mutated envelope proteins with reduced 
cross-reactivity (9,10). The ELISA was able to specifically 
detect the infecting DENV serotype in 84.4% of travel-
ers and 86.5% of residents in DENV-endemic regions. If 
a dominant serotype was detected, it corresponded to the 
PCR result in 100% of cases in DENV-endemic regions. 
The finding that some sample sets did not have a domi-
nant IgM serotype remains to be explained. Factors such 
as a change in the DENV serotype during an outbreak (as 
seen in the Sri Lanka cohort) or differing patient exposure 
histories could be involved. The study included DENV-
3–positive serum samples from returning travelers but not 
from persons residing in endemic regions. However, results 
obtained for the other serotypes indicate that specificities 
were similar for samples from returning travelers and in-
habitants of endemic areas.
In summary, our results suggest that specific IgM 
serotyping can be achieved with an ELISA-based format 
when using as antigens DENV envelope proteins reduced 
in cross-reactivity. The test can be optimized further by, 
for example, varying the serum dilutions tested. By using 
IgM-based serologic tests, which have broad diagnostic 
windows (15), we can more accurately report epidemio-
logic outbreak findings.
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